Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
2(14%)
Results Posted
14%(1 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_2
3
21%
Ph not_applicable
5
36%
Ph phase_4
5
36%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
3(23.1%)
Phase 4Post-market surveillance
5(38.5%)
N/ANon-phased studies
5(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

2

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(7)
Terminated(2)
Other(3)

Detailed Status

Completed7
unknown3
Recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
2
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (23.1%)
Phase 45 (38.5%)
N/A5 (38.5%)

Trials by Status

recruiting214%
unknown321%
terminated214%
completed750%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT03272698Phase 4

ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression

Recruiting
NCT06409325Not Applicable

Effectiveness of MST Versus ECT for Major Depressive Episode

Recruiting
NCT03849417

Brain Imaging Biomarkers of Pathological Brain Aging in Late-life Depression

Unknown
NCT03915821Not Applicable

Memory Changes in Patients With Major Depression Disorder Treated With ECT

Completed
NCT05047159Not Applicable

The Role of Neuromodulation Technique In Depression Disorder

Unknown
NCT01150513Phase 2

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Completed
NCT02659085Phase 2

Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder

Completed
NCT03507465Phase 2

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Unknown
NCT01260649Phase 4

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Terminated
NCT01028508Phase 4

Prolonging Remission in Depressed Elderly (PRIDE)

Completed
NCT01948999Not Applicable

Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study

Terminated
NCT02667353Not Applicable

Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression

Completed
NCT01559324Phase 4

Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression

Completed
NCT00922064Phase 4

Effects of Electroconvulsive Therapy (ECT) on Serotonin-1A Receptor Binding

Completed

All 14 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
14